Synlogic, Inc. (SYBX)

WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update.

WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update.

“Sell in May and go away” is a common adage in investing. It's based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines.

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.

Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.

CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.

Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process

Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release from Synlogic, this decision comes after an internal review of the clinical trial's progress.

Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU).

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study

- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -

- Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology - - Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology -

- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation -

- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 -

Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering.